813 results on '"Fotiou Despina"'
Search Results
2. Efficacy and immune modulation associated with the addition of IMiDs to Daratumumab backbone in multiple myeloma patients refractory to both drug classes: resetting synergistic activity
3. Characteristics and Outcomes of Patients With Relapsed/Refractory Multiple Myeloma After Exposure to Lenalidomide in First Line of Therapy: A Single Center Database Review in Greece
4. Mutations in the alternative complement pathway in multiple myeloma patients with carfilzomib-induced thrombotic microangiopathy
5. Dr. Raymond Alexanian: Pioneering Contributions to Multiple Myeloma Research, Treatment, and the Concept of Curability
6. Real World Efficacy and Toxicity of Selinexor: Importance of Patient Characteristics, Dose Intensity and Post Progression Outcomes
7. Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study
8. Low circulating tumor cell levels correlate with favorable outcomes and distinct biological features in multiple myeloma
9. ciRS‐7 circular RNA overexpression in plasma cells is a promising molecular biomarker of unfavorable prognosis in multiple myeloma
10. Monoclonal antibody-based therapies for Waldenström's macroglobulinemia
11. Longitudinal Changes of Cardiac Magnetic Resonance Parameters in Response to Treatment for Cardiac Light-Chain Amyloidosis
12. Small Fiber Neuropathy in AL Amyloidosis: Clinical and Prognostic Implications
13. Long-term hematologic remission in Immunoglobulin Light Chain (AL) Amyloidosis
14. Re-evaluation of Mayo 2004 and Revised Mayo 2012 staging in patients with AL amyloidosis in the era of new therapies
15. Exercise Rehabilitation in Patients with Cardiac Amyloidosis, a Case study
16. Left ventricular myocardial work improves in response to treatment and is associated with survival among patients with light chain cardiac amyloidosis
17. Efficacy and Safety of Daratumumab Monotherapy in Newly Diagnosed Patients with Stage 3B Light-Chain Amyloidosis: A Phase 2 Study by the European Myeloma Network
18. Efficacy and Safety of Belantamab Mafodotin Monotherapy in Patients with Relapsed or Refractory Light Chain Amyloidosis: A Phase 2 Study by the European Myeloma Network
19. Predictive value of free light chain burden in patients newly diagnosed with AL amyloidosis treated with CyBorD or DaraCyBorD
20. Poor neutralizing antibody responses in 106 patients with WM after vaccination against SARS-CoV-2: a prospective study
21. Carfilzomib-induced endothelial dysfunction, recovery of proteasome activity, and prediction of cardiovascular complications: a prospective study
22. Emerging treatment strategies for COVID-19 infection
23. Early Relapse After Autologous Transplant Is Associated With Very Poor Survival and Identifies an Ultra-High-Risk Group of Patients With Myeloma
24. Belantamab mafodotin, lenalidomide and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma: Part 1 results of a phase I/II study
25. Thrombotic and bleeding complications in patients with AL amyloidosis
26. Belantamab mafodotin, lenalidomide, and dexamethasone in transplant‐ineligible patients with newly diagnosed multiple myeloma: Analysis of belantamab mafodotin‐associated ocular adverse events and their impact on daily functioning from the part 1 of a phase 1/2 study
27. Exploring the molecular biomarker utility of circCCT3 in multiple myeloma: A favorable prognostic indicator, particularly for R‐ISS II patients
28. Impact of last lenalidomide dose, duration, and IMiD-free interval in patients with myeloma treated with pomalidomide/dexamethasone
29. Organ-specific manifestations of COVID-19 infection
30. Long PFS of more than 7 years is achieved in 9% of myeloma patients in the era of conventional chemotherapy and of first-generation novel anti-myeloma agents: a single-center experience over 20-year period
31. Clinical characteristics and outcomes of oligosecretory and non-secretory multiple myeloma
32. Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone
33. The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment
34. Management and Outcomes of Anti-CD38 Refractory Patients: The Impact of Retreatment and of Subsequent Therapies
35. Tixagevimab/Cilgavimab as Pre-Exposure Prophylaxis against COVID-19 for Multiple Myeloma Patients: A Prospective Study in the Omicron Era
36. P-301 Real-world outcomes of belantamab mafodotin monotherapy in triple class refractory patients with multiple myeloma
37. MM-527 Real World Evaluation of Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma (RRMM)
38. P-122 Ocular adverse events and functional impact in transplant ineligible, newly diagnosed multiple myeloma patients treated with belantamab mafodotin, lenalidomide and dexamethasone in BelaRd trial
39. P-426 Thrombotic and bleeding complications in patients with AL amyloidosis
40. P-477 Pre-exposure prophylaxis for COVID-19 with tixagevimab/cilgavimab (evusheld) in patients with multiple myeloma in the omicron SARS-COV-2 era
41. OA-13 Increased levels of circulating tumor cells correlate with adverse clinical outcomes and distinct biological features in newly diagnosed patients with multiple myeloma
42. OA-14 Persistent bone marrow and imaging MRD negativity may guide the duration of lenalidomide maintenance following ASCT in patients with multiple myeloma
43. POSTER: MM-527 Real World Evaluation of Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma (RRMM)
44. P-123 Safety and clinical activity of belantamab mafodotin plus lenalidomide and dexamethasone in transplant ineligible patients with newly diagnosed multiple myeloma: the phase 1/2 BelaRd study
45. P-154 Biomarker utility of circRNAs in multiple myeloma: the exemplary cases of ciRS-7 and circCCT3 as surrogate prognostic molecular biomarkers combined with the R-ISS staging system
46. MM-468 Longitudinal Assessment of Minimal Residual Disease Dynamics in Patients With Multiple Myeloma who Achieve Complete Response after First Line Therapy
47. Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosis
48. Discrepancies of current recommendations in breast cancer follow-up: a systematic review
49. Pulmonary function abnormalities are common in patients with multiple myeloma and are independently associated with worse outcome
50. Detection of MYD88 and CXCR4 mutations in cell-free DNA of patients with IgM monoclonal gammopathies
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.